[SCHEDULE 13G/A] Syndax Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Schedule 13G/A filed for Syndax Pharmaceuticals, Inc. reports that The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC jointly hold 5,581,828.06 shares of Syndax common stock, representing 6.5% of the class as reported for the event date 06/30/2025. The filing shows no sole voting or dispositive power and substantial shared voting power (5,581,718.06) and shared dispositive power (5,581,828.06). The cover exhibits include a joint filing agreement and identification of Goldman Sachs & Co. LLC as a subsidiary of GS Group. The registrants certify the securities are held in the ordinary course of business and not for the purpose of changing control.

Positive

• Institutional interest: The Goldman Sachs Group reports a 6.5% stake (5,581,828.06 shares) in SNDX, indicating significant institutional ownership.

Negative

• None.

Insights

Financial Analyst

TL;DR: Goldman Sachs discloses a material 6.5% stake in SNDX, showing notable institutional ownership but no sole control.

The Schedule 13G/A indicates a meaningful passive position by The Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC: 5,581,828.06 shares or 6.5% of Syndax common stock as of the reported event date. The filing records 0 sole voting and dispositive power while reporting nearly identical shared voting and dispositive figures, which implies the position is exercised collectively or through accounts managed by the adviser or broker-dealer. The filing includes a joint filing agreement and an exhibit identifying the subsidiary relationship. Impact to control is explicitly denied by certification.

Corporate Governance Expert

TL;DR: Institutional ownership above 5% triggers disclosure; the filing documents shared authority without a control intent.

The Schedule 13G/A is a routine disclosure when an institutional investor crosses the 5% threshold. It records shared voting power of 5,581,718.06 and shared dispositive power of 5,581,828.06, with 0 sole powers. The inclusion of Exhibit (99.1) confirms a joint filing agreement and Exhibit (99.2) clarifies the parent-subsidiary reporting relationship. The signatories explicitly state the securities are held in the ordinary course and not to influence control, aligning with Schedule 13G filing standards.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

SYNDAX PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

87164F105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 87164F105

1

Names of Reporting Persons

THE GOLDMAN SACHS GROUP, INC.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,581,718.06
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,581,828.06

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,581,828.06

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

HC, CO

SCHEDULE 13G

CUSIP No. 87164F105

1

Names of Reporting Persons

GOLDMAN SACHS & CO. LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEW YORK

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,581,718.06
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,581,828.06

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,581,828.06

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.5 %

12

Type of Reporting Person (See Instructions)

BD, OO, IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SYNDAX PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 730 THIRD AVENUE, 9TH FLOOR, NEW YORK, NY, X1,10017
Item 2.
(a)	Name of person filing: THE GOLDMAN SACHS GROUP, INC.| GOLDMAN SACHS & CO. LLC
(b)	Address or principal business office or, if none, residence: The Goldman Sachs Group, Inc. 200 West Street New York, NY 10282| Goldman Sachs & Co. LLC 200 West Street New York, NY 10282
(c)	Citizenship: THE GOLDMAN SACHS GROUP, INC. - Delaware| GOLDMAN SACHS & CO. LLC - New York
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 87164F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See the response(s) to Item 9 on the attached cover page(s).
(b)	Percent of class: See the response(s)to Item 11 on the attached cover page(s).
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See the response(s) to Item 5 on the attached cover page(s).
	(ii) Shared power to vote or to direct the vote: See the response(s) to Item 6 on the attached cover page(s).
	(iii) Sole power to dispose or to direct the disposition of: See the response(s) to Item 7 on the attached cover page(s).
	(iv) Shared power to dispose or to direct the disposition of: See the response(s) to Item 8 on the attached cover page(s).
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit (99.2)
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

THE GOLDMAN SACHS GROUP, INC.

Signature:	Name:
Name/Title:	Attorney-in-fact
Date:	07/17/2025

GOLDMAN SACHS & CO. LLC

Signature:	Name:
Name/Title:	Attorney-in-fact
Date:	07/17/2025

Exhibit Information

EXHIBIT (99.1) JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, of SYNDAX PHARMACEUTICALS, INC. and further agree to the filing of this agreement as an Exhibit thereto. In addition, each party to this Agreement expressly authorizes each other party to this Agreement to file on its behalf any and all amendments to such Statement on Schedule 13G. Date: 07/17/2025 THE GOLDMAN SACHS GROUP, INC. By:/s/ ---------------------------------------- Name: Title: Attorney-in-fact GOLDMAN SACHS & CO. LLC By:/s/ ---------------------------------------- Name: Title: Attorney-in-fact EXHIBIT (99.2) ITEM 7 INFORMATION The securities being reported on by The Goldman Sachs Group, Inc. ("GS Group"), as a parent holding company, are owned, or may be deemed to be beneficially owned, by Goldman Sachs & Co. LLC ("Goldman Sachs"), a broker or dealer registered under Section 15 of the Act and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940. Goldman Sachs is a subsidiary of GS Group.

FAQ

Who filed the Schedule 13G/A for SNDX?

The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC are the reporting persons.

How many Syndax (SNDX) shares are reported and what percent of the class do they represent?

5,581,828.06 shares, representing 6.5% of the class as reported on the filing cover.

What voting and dispositive powers are reported in the filing?

Sole voting power: 0.00; Shared voting power: 5,581,718.06; Sole dispositive power: 0.00; Shared dispositive power: 5,581,828.06.

What dates are shown on the Schedule 13G/A filing for SNDX?

Date of event requiring filing: 06/30/2025; Signature date: 07/17/2025.

Is this a joint filing and what exhibits are included?

Yes. Exhibit (99.1) is a joint filing agreement and Exhibit (99.2) identifies the subsidiary relationship between GS Group and Goldman Sachs & Co. LLC.